Skip to main content

Advertisement

SpringerLink
Log in

Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome

  • Clinical Trials
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

Children with steroid-dependent nephrotic syndrome experience serious side effects from steroid therapy. Cyclosporine A (CsA), which is an effective agent in the treatment of steroid-dependent nephrotic syndrome, is expensive and, consequently, often unaffordable in developing countries. Many studies have documented the benefit of ketoconazole administration in transplant adults treated with CsA. We have conducted a retrospective study with the objective of addressing cost-savings, safety, and the efficacy of the co-administration of ketoconazole and CsA to children with steroid-dependent nephrotic syndrome.

Methods

This study included 102 nephrotic patients who were steroid-dependent and who received cyclosporine therapy. The commonest pathologic lesions were focal segmental glomerulosclerosis (64 patients) and minimal change disease (36 patients). Among the patients participating in the study, 78 received daily ketoconazole therapy (ketoconazole group) in the form of a 50-mg dose accompanied by an initial one-third decrease in the CsA dose, while 24 received CsA alone (non- ketoconazole group). All of the patients were children (below 18 years), and the male-to-female ratio was 3:1. The mean duration of treatment was 22.9 months. The characteristics of both groups were comparable.

Results

Co-administration of ketoconazole significantly reduced mean doses of CsA by 48% with a net cost savings of 38%. It also resulted in a significant improvement in the CsA response and a more successful steroid withdrawal as well as a decrease in the frequency of renal impairment. Liver function tests remained normal in both groups up to and including the final follow-up (mean of 33.6 months).

Conclusions

The co-administration of ketoconazole to CsA in children with idiopathic steroid-dependent nephrotic syndrome safely results in a significant reduction in CsA cost, which causes great concern in developing countries. It may also improve CsA response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Begga A, Hari P, Moudgil A, Jordan S (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114–1120

    Article  Google Scholar 

  2. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE (1996) Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 7:543–549

    PubMed  CAS  Google Scholar 

  3. Neuhaus TJ, Burger HR, Klingler M, Fanconi A, Leumann EP (1992) Long-term cyclosporine therapy for pediatric nephrotic syndrome of childhood. Eur J Pediatr 151:775–778

    Article  PubMed  CAS  Google Scholar 

  4. Tejani A, Butt K, Trachtman H, Suthathiran M, Rothenthal CJ, Khawar MR (1988) Cyclosporine A induced remission of relapsing nephrotic syndrome of children. Kidney Int 33:729–734

    Article  PubMed  CAS  Google Scholar 

  5. Barclay PG, Allen RDM, Stewart JH, Ng K, Chapman JR (1992) Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc 24:165–166

    PubMed  CAS  Google Scholar 

  6. Smith SL, Hampton EM, Pederson JA (1994) Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 14:471–476

    PubMed  CAS  Google Scholar 

  7. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A (1995) Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628–633

    Article  PubMed  CAS  Google Scholar 

  8. Sobh M, El-Agroudy A, Mostafa F, Harras F, El-Bedewy M, Ghoneim M (1995) Co-administration of ketoconazole to cyclosporine treated kidney transplant recipients: a prospective randomized study. Am J Nephrol 15:493–499

    PubMed  CAS  Google Scholar 

  9. First MR, Schroeder TJ, Michela A, Hariharan S, Weiskittel P, Alexander JW (1993) Cyclosporine-ketoconazole interaction. Long-term follow up and preliminary results of a randomized trial. Transplantation 55:1000–1004

    Article  PubMed  CAS  Google Scholar 

  10. Jones TE (1997) The use of other drugs to allow a lower dosage of cyclosporine to be used: therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 32:357–367

    PubMed  CAS  Google Scholar 

  11. Sobh MA, Hamdy AF, El Agroudy AE, El Sayed K, El-Diasty T, Bakr MA, Ghoneim MA (2001) Co-administration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences. Am J Kidney Dis 37:510–517

    Article  PubMed  CAS  Google Scholar 

  12. Meyrier A, Niaudet P, Brodehl J (1992) Optimal use of Sandimmune in nephrotic syndrome. Springer, Berlin Heidelberg New York

    Google Scholar 

  13. International Study of Kidney Disease in Children (1982) Early identification of frequent relapsers among children with minimal change nephrotic syndrome. J Pediatr 101:514–518

    Article  Google Scholar 

  14. International Study of Kidney Disease in Children (1982) Primary nephrotic syndrome in children. Clinical significance of histopathologic variants of minimal change and diffuse mesangial hypercellularity. Kidney Int 20:717–765

    Google Scholar 

  15. Tune BM, Kirpeker R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy for prednisone-resistant pediatric focal glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88

    PubMed  CAS  Google Scholar 

  16. Everitt BS (1994) Statistical methods for medical investigators. 2nd edn. John Wiley & Sons, New York

    Google Scholar 

  17. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, Yoshioka K (1998) Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 31:932–939

    PubMed  CAS  Google Scholar 

  18. Tohjoh S, Narita M, Koyama T (1994) Clinical evaluation of cyclosporine in the treatment of nephrotic syndrome: Multi-center double blind study (in Japanese). Jin To Tohseki 37:565–608

    Google Scholar 

  19. Berkovitch M, Bitzan M, Matsui D, Finkelstein H, Balfe JW, Koren G (1994) Pediatric clinical use of the ketoconazole/cyclosporine interaction. Pediatr Nephrol 8:492–493

    Article  PubMed  CAS  Google Scholar 

  20. Kramer MR, Marshall SE, Denning DW et al (1990) Cyclosporine and itraconazole in heart and lung transplant recipients. Ann Intern Med 113:327–329

    PubMed  CAS  Google Scholar 

  21. Dieperink H, Kemp E, Leyssac PP et al (1986) Ketoconazole and cyclosporine A: combined effects on rat renal function and on serum and tissue cyclosporine A concentration. Clin Nephrol 25[Suppl 1]:S137–S143

    PubMed  CAS  Google Scholar 

  22. Buttman SM, Wild JC, Nolan PE, Fagan TC, Filney PR, Hick MJ, Capeland TG (1991) Prospective study of safety and financial benefit of ketoconazole as adjuvant therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 10:351–358

    Google Scholar 

  23. Glynn AM, Slaughter RL, Brass C, D’Ambrosio R, Jusko WJ (1986) Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 39:654–659

    Article  PubMed  CAS  Google Scholar 

  24. Ganesan V, Milford V, Taylor C, Hulton S, Parvaresh S, Ramani P (2002) Cyclosporine-related nephrotoxicity in children with nephrotic syndrome. Pediatr Nephrol 17:225–226

    Article  PubMed  CAS  Google Scholar 

  25. Singh A, Tejani C, Tejani A (1999) One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 13:26–32

    Article  PubMed  CAS  Google Scholar 

  26. Senior DS, Show JT (1988) In vitro effect of fluconazole and ketoconazole on mouth lymphocyte proliferation and on Canadian blastospore destruction by human polymorphonuclear leucocytes. Int J Immuno Pharmacol 10:169–176

    Article  CAS  Google Scholar 

  27. Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two-year cyclosporine treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 13:33–38

    Article  PubMed  CAS  Google Scholar 

  28. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A (1995) Aggressive, long-term cyclosporine therapy for steroid resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 5:1820–1825

    PubMed  CAS  Google Scholar 

  29. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North American Nephrotic Syndrome Study Group. Kidney Int 56:2220–2226

    Article  PubMed  CAS  Google Scholar 

  30. Chishti AS, Sorof JM, Brewer ED, Kale AS (2001) Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 38:754–760

    PubMed  CAS  Google Scholar 

  31. Lorber MI, Van Buren CT, Flechner SM (1987) Hepatobiliary and pancreatic complications of Cyclosporine therapy in 1466 transplant recipients. Transplantation 43:35–40

    Article  PubMed  CAS  Google Scholar 

  32. First MR, Schroeder TJ, Alexander JW, Stephens GW, Weiskittle P, Pesce AJ (1991) Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51:365–370

    Article  PubMed  CAS  Google Scholar 

  33. McEvoy GK (ed) (1991) Ketoconazole. In: AHFS drug information. American Society of Health-System Pharmacists, Bethesda, pp 82–86

Download references

Author information

Authors and Affiliations

  1. Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

    Amr El-Husseini, Fathy El-Basuony, Ihab Mahmoud, Ahmed Donia, Hussein Sheashaa, Alaa Sabry, Nabil Hassan, Nagy Sayed-Ahmad & Mohamed Sobh

Authors
  1. Amr El-Husseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fathy El-Basuony
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ihab Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Donia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hussein Sheashaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alaa Sabry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nabil Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nagy Sayed-Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohamed Sobh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Sobh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Husseini, A., El-Basuony, F., Mahmoud, I. et al. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. Eur J Clin Pharmacol 62, 3–8 (2006). https://doi.org/10.1007/s00228-005-0064-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0064-0

Keywords

Search

Navigation